💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Y-mAbs Therapeutics signs new headquarters lease

EditorLina Guerrero
Published 09/17/2024, 06:04 PM
YMAB
-

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a pharmaceutical company, announced on Monday that it has entered into a lease agreement for a new corporate headquarters in Princeton, New Jersey. The lease, signed on September 11, 2024, with Princeton 202 Associates Limited Partnership, secures approximately 10,817 square feet of space at 202 Carnegie Center.

The company plans to relocate to the new premises in the first half of 2025, following the completion of the space's fitout. The initial lease term is set for 10 years and nine months, with the company holding two options to extend for five additional years each. While the fitout is underway, Y-mAbs will occupy roughly 5,040 square feet of office space in the same location.

Over the initial term, the base rent payment is estimated to be around $3.9 million. The lease agreement includes standard clauses where the company will cover its share of operating expenses, taxes, and certain fees connected to the property. It also allows the lessor to terminate the lease if the company defaults under certain conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.